Tumor Cell Injection
Tumor Cell Injection - Related Videos
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
04:08
Intracecal Tumor Cell Injection: A Technique to Deliver Cancer Cells for Establishing Orthotopic Colorectal Cancer Mouse Model
0 Views •
2023
The video describes the technique for intracecal injection of cancerous cells to develop an orthotopic mouse model with highly uniform tumors. Therefore, the orthotopic mouse model allows realistic simulation of metastasis, providing a valuable tool to study the phenotype changes during tumor growth and dissemination.
03:42
Modeling Brain Tumor Metastasis via Internal Carotid Artery Injection of Cancer Cells
0 Views •
2025
Source: Lim, M., et al. Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells. J. Vis. Exp. (2022)In this video, an anesthetized mouse undergoes a surgical procedure in which cancer cells are injected into the common carotid artery (CCA) to facilitate targeted delivery to the brain. The procedure involves precise suturing and manipulation of the carotid arteries to direct the injected cells toward the internal carotid artery (ICA), promoting tumor formation in the brain...
04:10
Surgical Cisterna Magna Injection: A Method for Administering Tumor Cells Directly into Central Nervous System of Murine Model
0 Views •
2023
In this video, we describe the procedure to deliver human-derived tumor cells into the cisterna magna of a mouse’s brain. The orthotopic mouse model can be used to study metastatic spread of cancer to the cranial meninges.
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
0 Views •
2025
This protocol describes the in vivo reprogramming of mouse cancer cells into type 1 dendritic-like cells within the tumor microenvironment through enforced expression of the transcription factors PU.1, IRF8, and BATF3.
FAQs
After introduction, surviving tumor cells interact with surrounding stromal cells and immune cells, so growth reflects more than tumor-cell proliferation alone. These interactions can reveal whether the local environment supports expansion or contributes to immune control. In immunology research, examining this relationship helps connect changes in the tumor microenvironment with antitumor responses and immune evasion.
Three variables are especially important: the injection site, the number of cells introduced, and the host’s immune status. Changing the site can alter local interactions, while cell number may influence tumor growth. Comparing different host immune states can clarify how immunity shapes tumor progression and whether changes in growth reflect altered tumor-immune interactions.
Localized models are useful for examining interactions at a defined tissue site, whereas disseminated models can support analysis of tumor behavior across a broader distribution. Comparing the two can help determine whether an immune response or therapeutic effect depends on the anatomical setting, while relating tumor growth to surrounding stromal and immune cells.
A basic workflow begins with cultured tumor cells, followed by introduction into a selected animal or tissue site. Researchers then vary or control relevant conditions, such as cell number and host immune status, according to the experimental question. Subsequent measurements of tumor growth and tumor-immune interactions provide a basis for comparing groups and linking model conditions to outcomes.
The model can characterize antitumor immune responses and investigate immune evasion. It also provides an experimental setting for evaluating vaccines or immunotherapies, and for testing infectious agents that alter tumor-immune interactions. These applications allow researchers to examine how an intervention or exposure changes tumor growth alongside the host response, connecting immune mechanisms with therapeutic outcomes.
Researchers can compare tumor growth under different injection sites, cell numbers, or immune states, then relate those differences to surrounding stromal and immune-cell interactions. The resulting patterns may indicate whether a condition promotes tumor expansion, strengthens antitumor activity, or changes immune evasion. This interpretation also helps connect cellular mechanisms with disease progression and treatment outcomes.